US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma

被引：7
|
作者：
Betts, Keith A. [1 ]
Thuresson, Per-Olof [2 ]
Felizzi, Federico [2 ]
Du, Ella X. [1 ]
Dieye, Ibou [3 ]
Li, Jia [4 ]
Schulz, Mathias [4 ]
Masaquel, Anthony S. [4 ]
机构：
[1] Anal Grp Inc, Los Angeles, CA 90071 USA
[2] F Hoffmann La Roche Ltd, Basel, Switzerland
[3] Anal Grp Inc, Boston, MA 02199 USA
[4] Genentech Inc, San Francisco, CA 94080 USA
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2020年 / 9卷 / 14期
关键词：
bendamustine; cost-effectiveness; DLBCL; polatuzumab vedotin; relapsed; refractory; rituximab; SALVAGE REGIMENS; TRANSPLANTATION;
D O I：
10.2217/cer-2020-0057
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Aim: To evaluate the cost-effectiveness of polatuzumab vedotin (pola) + bendamustine + rituximab (BR) in relapsed/refractory diffuse large B-cell lymphoma based on the GO29365 trial from a US payer's perspective.Materials & methods: A partitioned survival model used progression-free survival and overall survival data from the GO29365 trial. The base case analysis assumed overall survival was informed by progression-free survival; a mixture cure model estimated proportion of long-term survivors.Results:In the base case, pola + BR was cost-effective versus BR at US$35,864 per quality-adjusted life year gained. Probabilistic and one-way sensitivity analyses showed that the findings were robust.Conclusion:Pola + BR is cost-effective versus BR for the treatment of transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma in the US.
引用
收藏
页码：1003 / 1015
页数：13
相关论文
共 50 条
  • [1] US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma (vol 9, pg 1003, 2020)
    Betts, Keith A.
    Thuresson, Per-Olof
    Felizzi, Federico
    Du, Ella X.
    Dieye, Ibou
    Li, Jia
    Schulz, Mathias
    Masaquel, Anthony S.
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (04) : 337 - 337
  • [2] COST-EFFECTIVENESS AND COST-UTILITY ANALYSES OF POLATUZUMAB VEDOTIN WITH BENDAMUSTINE AND RITUXIMAB VS. BENDAMUSTINE AND RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
    Bellone, M.
    Pradelli, L.
    Caputo, A.
    Ghislieri, D.
    Launonen, A.
    Ho, R.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S82 - S82
  • [3] US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma
    Matasar, Matthew
    Masaquel, Anthony
    S. Ho, Rodrigo
    Launonen, Aino
    Ng, Carmen D.
    Wang, Rongrong
    Fox, David
    Hossain, Farah
    Li, Jia
    Burke, John M.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 1134 - 1144
  • [4] Cost-Effectiveness of Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
    Matasar, Matthew
    Masaquel, Anthony
    Rodrigo, Ho
    Launonen, Aino
    Ng, Carmen
    Wang, Rongrong
    Fox, David
    Hossain, Farah
    Li, Jia
    Roth, Joshua A.
    Burke, John M.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S359 - S360
  • [5] Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma
    Patel, Kishan K.
    Isufi, Iris
    Kothari, Shalin
    Foss, Francine
    Huntington, Scott
    [J]. LEUKEMIA & LYMPHOMA, 2020, 61 (14) : 3387 - 3394
  • [6] Cost-Effectiveness Analysis of Frontline Treatment with Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
    Fu, Yu-Hua
    Wu, Shang-Ju
    Tan, Elise Chia-Hui
    Wang, Chi-Chuan
    Kim, Kibum
    Chou, Wen-Chien
    Lin, Fang-Ju
    [J]. BLOOD, 2022, 140 : 10808 - 10809
  • [7] Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma
    Kambhampati, Swetha
    Saumoy, Monica
    Schneider, Yecheskel
    Pak, Stacy
    Budde, Lihua Elizabeth
    Mei, Matthew G.
    Siddiqi, Tanya
    Popplewell, Leslie L.
    Wen, Yi-Ping
    Zain, Jasmine
    Forman, Stephen J.
    Kwak, Larry W.
    Rosen, Steven T.
    Danilov, Alexey V.
    Herrera, Alex F.
    Thiruvengadam, Nikhil R.
    [J]. BLOOD, 2022, 140 (25) : 2697 - 2708
  • [8] Cost-Effectiveness of Polatuzumab Vedotin Plus Bendamustine-Rituximab for Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the United States
    Betts, Keith A.
    Felizzi, Federico
    Dieye, Ibou
    Li, Jia
    Schulz, Mathias
    Hong, Samuel J.
    Masaquel, Anthony S.
    [J]. BLOOD, 2020, 136
  • [9] A COST-EFFECTIVENESS ANALYSIS OF POLATUZUMAB IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN PORTUGAL
    Pinheiro, B.
    Cardoso, M.
    Borges, M.
    Launonen, A.
    Ho, R.
    Miguel, Silva L.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S43 - S44
  • [10] Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab
    Amaya, M. L.
    Jimeno, A.
    Kamdar, M.
    [J]. DRUGS OF TODAY, 2020, 56 (04) : 287 - 294
12345